Risk Factors for New-Onset Diabetes Mellitus in Patients Receiving Protease Inhibitor Therapy

Christine A Hughes; Richard P Cashin; Dean T Eurich; Stan Houston

doi:10.1155/2005/971971

Canadian Journal of Infectious Diseases and Medical Microbiology (Jan 2005)

Risk Factors for New-Onset Diabetes Mellitus in Patients Receiving Protease Inhibitor Therapy

Christine A Hughes,
Richard P Cashin,
Dean T Eurich,
Stan Houston

Affiliations

Christine A Hughes: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, and the Capital Health Region, Edmonton, Alberta, Canada
Richard P Cashin: Saskatoon Health Region, Saskatoon, Saskatchewan, Canada
Dean T Eurich: Institute of Health Economics and the Department of Public Health Sciences, University of Alberta, Canada
Stan Houston: Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada

DOI: https://doi.org/10.1155/2005/971971
Journal volume & issue: Vol. 16, no. 4
pp. 230 – 232

Abstract

Read online

BACKGROUND: Metabolic complications including diabetes mellitus (DM) have been associated with protease inhibitor (PI) therapy. Risk factors for the development of DM are not well-defined.

Published in Canadian Journal of Infectious Diseases and Medical Microbiology

ISSN: 1712-9532 (Print); 1918-1493 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Infectious and parasitic diseases; Science: Microbiology
Website: https://onlinelibrary.wiley.com/journal/9575

About the journal